PEPTIDE CORTEXThe library
← The library

ARA-290

Cibinetide, researchHealing/Recovery
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeHealing / Recovery
MechanismNon-erythropoietic EPO-derived peptide targeting the innate repair receptor; studied in small-fibre neuropathy
EffectsStudied for nerve repair and inflammatory signalling without the blood-thickening effects of EPO
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published3 sourced
Clinical trialPhase 2, type 2 diabetes with neuropathy (Brines 2014)
RouteSubcutaneous
FrequencyOnce daily, 28 days
Starting4 mg SC daily
EscalationNone
Target4 mg SC daily for 28 days
Clinical trialPhase 2b, sarcoidosis small-fibre neuropathy
RouteSubcutaneous
FrequencyOnce daily, 28 days
StartingArms: 1, 4 or 8 mg SC daily
EscalationNone
Target1, 4 or 8 mg SC daily for 28 days

Arms as tabulated by the community guide; only the Brines 2014 regimen was independently confirmed.

Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous (abdominal fat or thigh, rotated)
FrequencyOnce daily
Starting1-4 mg/day
Escalation"Up to 8 mg/day (trial ceiling)"
Target4 mg once daily
Cycle"About 4 weeks, matching trial blocks"
WhereAbdominal fat or thigh, rotated.
Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Not FDA-approved; avoid self-administration; unverified sourcing and purity

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — Designed specifically to avoid EPO’s haematocrit and thrombotic effects, but no cardiovascular outcomes data exists.